Volume 15, Issue 6, Pages (June 2007)

Slides:



Advertisements
Similar presentations
Molecular Therapy - Oncolytics
Advertisements

Volume 10, Issue 2, Pages (August 2004)
Molecular Therapy - Oncolytics
Molecular Therapy - Oncolytics
Volume 18, Issue 2, Pages (February 2010)
Immunologic Characterization of HIV-Specific DNA Vaccine
Volume 15, Issue 2, Pages (February 2007)
Volume 17, Issue 8, Pages (August 2009)
Molecular Therapy - Oncolytics
Mohan Babu Appaiahgari, Sudhanshu Vrati  Molecular Therapy 
Volume 15, Issue 12, Pages (December 2007)
Volume 10, Issue 5, Pages (November 2004)
Prevention of Genital Herpes Simplex Virus Type 1 and 2 Disease in Mice Immunized with a gD-Expressing Dominant-Negative Recombinant HSV-1  Richard Brans,
Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model  Debanjan.
Volume 8, Issue 4, Pages (October 2003)
Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer  Svend O Freytag, Yingshu Zhang,
Volume 10, Issue 6, Pages (December 2004)
Volume 4, Issue 3, Pages (September 2008)
Volume 17, Issue 8, Pages (August 2009)
Volume 18, Issue 11, Pages (November 2010)
Molecular Therapy - Oncolytics
Volume 18, Issue 9, Pages (September 2010)
Volume 3, Issue 2, Pages (February 2001)
Molecular Therapy - Oncolytics
Volume 22, Issue 1, Pages (January 2014)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Volume 9, Issue 6, Pages (June 2004)
Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models  Fabrice Le Boeuf, Simon Gebremeskel,
Volume 2, Issue 4, Pages (October 2000)
Volume 26, Issue 4, Pages (April 2018)
Volume 23, Issue 6, Pages (June 2015)
Volume 12, Issue 5, Pages (November 2005)
Hannah Chen, Padma Sampath, Weizhou Hou, Stephen H. Thorne 
Volume 16, Issue 6, Pages (June 2008)
Volume 18, Issue 10, Pages (October 2010)
Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8+ T-cell Activation Against Tumors  Benjamin J Umlauf, Chin-Ying.
Thomas S. Griffith, Elizabeth L. Broghammer  Molecular Therapy 
Volume 22, Issue 1, Pages (January 2014)
Volume 22, Issue 1, Pages (January 2014)
Lukxmi Balathasan, Vera A
Volume 20, Issue 5, Pages (May 2012)
Volume 24, Issue 1, Pages (January 2016)
Ajay Gautam, Charles L. Densmore, J.Clifford Waldrep  Molecular Therapy 
Maraba Virus as a Potent Oncolytic Vaccine Vector
Volume 6, Issue 3, Pages (September 2002)
Volume 18, Issue 12, Pages (December 2010)
Volume 26, Issue 1, Pages (January 2018)
Volume 15, Issue 1, Pages (January 2007)
Volume 21, Issue 4, Pages (April 2013)
Volume 17, Issue 10, Pages (October 2009)
Volume 19, Issue 10, Pages (October 2011)
Valerie Künzi, Patrick A
Volume 10, Issue 6, Pages (December 2004)
Volume 18, Issue 3, Pages (March 2010)
Molecular Therapy - Oncolytics
Volume 6, Issue 5, Pages (November 2002)
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity  Tomer Granot,
Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response  Arup Garu, Gopikrishna.
Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer
Volume 20, Issue 4, Pages (April 2012)
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism  Johann Foloppe, Juliette.
Systemic Administration of Platelets Incorporating Inactivated Sendai Virus Eradicates Melanoma in Mice  Tomoyuki Nishikawa, Li Yu Tung, Yasufumi Kaneda 
Volume 20, Issue 6, Pages (June 2012)
Volume 3, Issue 5, Pages (May 2001)
Volume 18, Issue 10, Pages (October 2010)
Molecular Therapy - Oncolytics
Volume 18, Issue 2, Pages (February 2010)
Volume 15, Issue 2, Pages (February 2007)
Volume 22, Issue 1, Pages (January 2014)
Volume 12, Issue 5, Pages (November 2005)
Presentation transcript:

Volume 15, Issue 6, Pages 1121-1128 (June 2007) Carrier Cell–mediated Delivery of a Replication-competent Adenovirus for Cancer Gene Therapy  Katsuyuki Hamada, Junzo Desaki, Kou Nakagawa, Ting Zhang, Toshiro Shirakawa, Akinobu Gotoh, Masatoshi Tagawa  Molecular Therapy  Volume 15, Issue 6, Pages 1121-1128 (June 2007) DOI: 10.1038/sj.mt.6300128 Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 1 Viral production and cytotoxicity of AdE3-IAI.3B-infected cells. (a) Viral production of AdE3-IAI.3B or AdE3 in cell lysates (cell) and supernatants (supt). (b) Cytotoxicity of AdE3-IAI.3B-infected cells against ovarian cancer PA-1 cells was determined by cell count assay. Values in a and b are the means ± SD for five replicates. PFU, plaque-forming unit; IC50, 50% growth inhibitory concentration. Molecular Therapy 2007 15, 1121-1128DOI: (10.1038/sj.mt.6300128) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 2 Anti-tumor effects of AdE3-IAI.3B alone and AdE3-IAI.3B-infected A549, 293, and SW626 carrier cells on subcutaneous PA-1 (a) and RMG-1 (b) tumor growth in nude mice. Mice were intra-tumorally injected with medium alone, AdE3-IAI.3B alone, or AdE3-IAI.3B-infected A549, 293, and SW626 carrier cells on days 0, 1, 2, 3, 4, and 5. Values in a and b are the means ± SD for ten female nude mice. Molecular Therapy 2007 15, 1121-1128DOI: (10.1038/sj.mt.6300128) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 3 Effects of immunization with Ad-β-gal or UV-inactivated Ad-β-gal on survival of OVHM tumor–bearing mice that received AdE3-IAI.3B- and/or AxCAmGM-CSF-infected A549 and/or 293 carrier cells. (a) Mice were intra-tumorally injected with medium alone, AdE3-IAI.3B alone, or AdE3-IAI.3B-infected A549 carrier cells with or without immunization on days 0, 1, 2, 3, 4, and 5. (b) After one (×1), two (×2), or three (×3) immunizations with Ad-β-gal, mice were treated with AdE3-IAI.3B-infected A549 carrier cells on days 0, 1, 2, 3, 4, and 5. (c) After immunization with Ad-β-gal or UV-inactivated Ad-β-gal, mice were treated with A549 carrier cells infected with AdE3-IAI.3B and/or AxCAmGM-CSF on days 0, 1, and 2. (d) After immunization with Ad-β-gal or UV-inactivated Ad-β-gal, mice were treated with A549 and/or 293 carrier cells co-infected with AdE3-IAI.3B and AxCAmGM-CSF on day 0. Values in a, b, c, and d are the means ± SD for ten female (C57BL/6 × C3H/He) F1 mice. Molecular Therapy 2007 15, 1121-1128DOI: (10.1038/sj.mt.6300128) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 4 Carrier cells circumvent adenoviral humoral immune responses and induce tumor-specific immunity. (a) Time course of change in anti-adenovirus antibody titer after subcutaneous injection of Ad-β-gal (Ad) or UV-inactivated Ad-β-gal (UV) in syngeneic mice. Serum samples were collected 3, 6, 9, and 12 weeks (wk) after a single injection (×1) of Ad-β-gal (black column) or UV-inactivated Ad-β-gal(gray column). Serum samples were also collected 3 weeks after the first (×1), second (×2), and third injections (×3) of Ad-β-gal, and 6 weeks after the third injection (×3) of Ad-β-gal (white column). AdE3-IAI.3B-infectedHT-3, SW626, A549, and 293 cells inhibited growth of PA-1 cells in medium with (Ab (+)) or without (Ab (−)) anti-adenovirus antibody, but AdE3-IAI.3B did so only in medium without anti-adenovirus antibody (Ab (−)) (b). (c) A549 carrier cells with or without three freeze-and-thaw cycles after infection with AdE3-IAI.3B for 24 hours were incubated in anti-adenovirus antibody–containing medium for 10 days with separation from adherent target PA-1 cells by Millicell filter chambers (0.4 μm, 12 μm). (d) Splenic lymphocytes were isolated from tumor-bearing syngeneic mice after injection of phosphate-buffered saline, Ad-β-gal, and UV-inactivated Ad-β-gal(UV-Ad-β-gal), and from mice with complete tumor regression after injection of A549 carrier cells infected with AdE3-IAI.3B or with AdE3-IAI.3B and AxCAmGM-CSF after immunization with Ad-β-gal. OVHM cells infected with Ad-β-gal(Ad-OVHM) or uninfectedcells (OVHM) were used as target cells for the assay of cytotoxic T-lymphocyte (CTL) activity. Values in a, b, c, and d are the means ± SD for five replicates. Molecular Therapy 2007 15, 1121-1128DOI: (10.1038/sj.mt.6300128) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 5 Electron micrographs of A549 carrier cells and of A549 and PA-1 target cells. (a) Control A549 cells generated microvilli and short cytoplasmic processes (arrows). A549 carrier cells were infected with AdE3-IAI.3B for 24 hours, harvested, and then cultured with target A549 cells for 24 hours. A549 carrier cells generated viral particle–containing blebs (arrow) (b) and delivered viral particle–containing cell fragment vesicles (arrows) (c). (d) Nuclei and intracellular organelles of A549 carrier cells still contained viral particles after necrosis. Viral particle–containing cell fragments (arrow) were captured by cytoplasmic processes of target A549 cells (e) and directly infected cytoplasmic process of target A549 cell with viruses (arrow) (f). (g) A viral particle–containing cell fragment (arrows) engulfed by a target A549 cell. (h) Control PA-1 target cells had cytoplasmic processes (arrow). AdE3-IAI.3B-infected A549 carrier cells were harvested and cultured with target PA-1 cells for 24 hours. (i) A viral particle–containing cell fragment (arrow) engulfed by a target PA-1 cell. C and T, carrier and target cells, respectively. The scale bar in the lower right corner of each figure indicates 1 μm. Molecular Therapy 2007 15, 1121-1128DOI: (10.1038/sj.mt.6300128) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions